GlaxoSmithKline expands API production for COPD inhalers as Advair sales wither

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 23, 2018 at 1:42 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,730
    Likes Received:
    3
    via Even with looming generic competition expected to take a big bite out of sales of its blockbuster Advair, respiratory drugs remain key to GlaxoSmithKline, and it continues to plow money into their production. The latest project is an expansion to make APIs for one of its COPD drugs that it is leaning on as Advair revenue shrinks.

    article source